Peptides, Год журнала: 2022, Номер 157, С. 170866 - 170866
Опубликована: Сен. 5, 2022
Язык: Английский
European Journal of Heart Failure, Год журнала: 2023, Номер 25(9), С. 1507 - 1525
Опубликована: Авг. 10, 2023
Язык: Английский
Процитировано
36
International Journal of Cardiology, Год журнала: 2024, Номер 402, С. 131818 - 131818
Опубликована: Фев. 1, 2024
Язык: Английский
Процитировано
13
Journal of Cardiac Failure, Год журнала: 2025, Номер unknown
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
2
AJP Heart and Circulatory Physiology, Год журнала: 2023, Номер 324(4), С. H443 - H460
Опубликована: Фев. 10, 2023
Heart failure (HF) with preserved ejection fraction (HFpEF) is defined as HF an (EF) ≥ 50% and elevated cardiac diastolic filling pressures. The underlying causes of HFpEF are multifactorial not well-defined. A transgenic mouse low levels cardiomyocyte (CM)-specific inducible Cavβ2a expression (β2a-Tg mice) showed increased cytosolic CM Ca
Язык: Английский
Процитировано
14
Frontiers in Cardiovascular Medicine, Год журнала: 2023, Номер 9
Опубликована: Янв. 12, 2023
In the past few decades, non-alcoholic fatty liver disease (NAFLD) and heart failure with preserved ejection fraction (HFpEF) have become most common chronic main form of (HF), respectively. NAFLD is closely associated HFpEF by sharing risk factors and/or boosting systemic inflammation, releasing other secretory factors, having an expansion epicardial adipose tissue (EAT). Therefore, treatments may also affect development prognosis HFpEF. However, no specific drugs for been approved Food Drug Administration (FDA) some non-specific are applied in clinic. Currently, can be divided into non-pharmacological pharmacological treatments. Non-pharmacological mainly include dietary intervention, weight loss exercise, caloric restriction, bariatric surgery. Pharmacological administering statins, thiazolidinediones, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, metformin. This review will focus on analyzing how these
Язык: Английский
Процитировано
9
American Journal of Preventive Cardiology, Год журнала: 2025, Номер unknown, С. 100928 - 100928
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
0
Clinical Autonomic Research, Год журнала: 2025, Номер unknown
Опубликована: Фев. 26, 2025
Язык: Английский
Процитировано
0
Biomolecules, Год журнала: 2025, Номер 15(5), С. 670 - 670
Опубликована: Май 6, 2025
Cardiomyopathies comprise a heterogeneous group of cardiac disorders characterized by structural and functional abnormalities in the absence significant coronary artery disease, hypertension, valvular or congenital defects. Major subtypes include hypertrophic, dilated, arrhythmogenic, stress-induced cardiomyopathies. Oxidative stress (OS), resulting from an imbalance between reactive oxygen species (ROS) production antioxidant defenses, has emerged as key contributor to pathogenesis these conditions. ROS-mediated injury drives inflammation, protease activation, mitochondrial dysfunction, cardiomyocyte damage, thereby promoting remodeling decline. Although numerous studies implicate OS cardiomyopathy progression, precise molecular mechanisms remain incompletely defined. This review provides updated synthesis current findings on OS-related signaling pathways across subtypes, emphasizing emerging therapeutic targets within redox-regulatory networks. A deeper understanding may guide development targeted strategies improve clinical outcomes affected patients.
Язык: Английский
Процитировано
0
Frontiers in Cardiovascular Medicine, Год журнала: 2025, Номер 12
Опубликована: Май 27, 2025
Background Finerenone has been shown to improve outcomes in patients with heart failure (HF), encompassing those reduced (HFrEF), mildly (HFmrEF), or preserved ejection fraction (HFpEF). However, its clinical use is accompanied by notable adverse effects. This study aimed evaluate the relative risks of events associated finerenone across HF phenotypes. Methods A systematic search PubMed, Embase, and Web Science identified six randomized controlled trials involving 8,527 patients. The analysis considered hyperkalemia, hypotension, treatment-emergent (TEAEs), serious (TESAEs), treatment discontinuation due events. Results significantly increased risk hyperkalemia (RR = 2.07, 95% CI 1.77-2.44, P < 0.00001) hypotension 1.49, 1.31-1.68, compared placebo, irrespective phenotype. No significant differences were observed between placebo terms TEAEs, TESAEs, when analyzing overall population. Compared eplerenone, was a lower TEAEs 0.93, CI: 0.89-0.98) TESAEs 0.74, 0.66-0.84), similar rates. Additionally, one included suggested that may have 0.64, 0.56-0.74), 0.37, 0.25-0.54) 0.41, 0.21-0.79) spironolactone, rates 0.61, 0.29-1.30) HFrEF. Conclusion (10-25 mg) showed safety profile no discontinuation. fewer comparable Moreover, HFrEF, offer discontinuation, than hypotension.
Язык: Английский
Процитировано
0
International Journal of Molecular Sciences, Год журнала: 2022, Номер 23(23), С. 15140 - 15140
Опубликована: Дек. 1, 2022
Aging is an important risk factor for the development of heart failure (HF) and half patients with HF have preserved ejection fraction (HFpEF) which more common in elderly women. In general, sex differences that lead to discrepancies factors cardiovascular disease (CVD) been attributed reduced level circulating estrogen during menopause. Estrogen receptors adaptively modulate fibrotic, apoptotic, inflammatory processes calcium homeostasis, are directly involved HFpEF. Therefore, menopause, depletion reduces cardioprotection. Preclinical menopause models demonstrated several signaling pathways organ systems closely HFpEF, including dysregulation renin-angiotensin system (RAS), chronic process alteration sympathetic nervous system. Thus, this review explores thealterations observed condition HFpEF induced by therapeutic targets potential interfere progress.
Язык: Английский
Процитировано
14